Clinical Trial: Premature Aging and Type 2 Diabetes Mellitus: an Increased Risk of Cardiomyopathy?

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Premature Aging and Type 2 Diabetes Mellitus: an Increased Risk of Cardiomyopathy?

Brief Summary:

The potential clinical implications of this study are to optimise the selection of a population at risk for developing a diabetic cardiomyopathy among diabetic patients in order to develop early therapeutic strategies to prevent the left ventricular remodelling.

Therefore, the originality of this project is to hypothesize that :

  • Diabetes mellitus is often associated with a premature aging syndrome
  • Cellular senescence may potentiate the mechanisms that are involved in decreasing myocardial contractility in DM and,
  • DM associated to premature aging may increase the risk of developing a cardiomyopathy Thus, the modulation of telomerase activity and the control of telomere length, together with the attenuation of the formation of reactive oxygen species, might represent important new targets in order to develop therapeutic tools in prevention of diabetic cardiomyopathy.

Detailed Summary:
Sponsor: Hospices Civils de Lyon

Current Primary Outcome: Telomere shortening [ Time Frame: 36 months ]

Investigate whether biomarkers for senescence determined from blood samples, including telomere shortening and telomerase activity in diabetic patients have an impact of left ventricular remodelling as compared with age-matched controls and biological aged control subjects.


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Dysfunction by speckle tracking imaging [ Time Frame: 36 months ]
    Study the incidence of subtle regional myocardial dysfunction by speckle tracking imaging (longitudinal and radial systolic strain)
  • Determine the predictive value of alteration [ Time Frame: 36 months ]
    Determine the predictive value of alteration : Proteinuria, glycosylated haemoglobin, diabetes mellitus duration, blood pressure, BNP dosage, MRI diagnoses
  • Cardiovascular events [ Time Frame: 36 months ]
    Investigate the predictive value of all those factors( telomere shortening, telomerase activity, echo abnormalities) on cardiovascular events including MI, HF, arrhythmia; ACV


Original Secondary Outcome: Same as current

Information By: Hospices Civils de Lyon

Dates:
Date Received: February 16, 2012
Date Started: April 2009
Date Completion:
Last Updated: March 31, 2015
Last Verified: August 2010